Cytonus Therapeutics Becomes Axiom Biosciences, Pairing Its Regenerative Medicine Programs With AI-Enabled Drug DesignSAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences, a clinical-stage biotechnology company developing next-generation regenerative therapies and targeted biologics, today announced its corporate rebranding from Cytonus Therapeutics. The new name reflects the company’s growth from a regenerative medicine innovator into a broader therapeutics company that pairs its clinical-stage cell therapy programs with AI-enabled drug design and targeted delivery technologies.
